<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MANNITOL- mannitol injection, solution </strong><br>B. Braun Medical Inc.<br></p></div>
<h1>20% Mannitol Injection USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3145148a-54fb-49ce-812b-1f2167766a38"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">For Therapeutic Use Only</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_0d411926-af1b-431c-aba4-d22173be13cb"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">20% Mannitol Injection USP is a sterile, nonpyrogenic solution of Mannitol USP in a single dose container for intravenous administration. It contains no antimicrobial agents. Mannitol is a 6-carbon sugar alcohol prepared commercially by the reduction of dextrose. Although virtually inert metabolically in humans, it occurs naturally in fruits and vegetables. Mannitol is an obligatory osmotic diuretic.</p>
<p>Each 100 mL contains:<br>Mannitol USP 20 g; Water for Injection USP qs<br><br>pH: 5.3 (4.5–7.0); Calculated Osmolarity 1100 mOsmol/liter</p>
<p>Administration of substantially hypertonic solutions (≥ 600 mOsmol/L) may cause vein damage. Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L.</p>
<p>The formula of the active ingredient is:</p>
<table>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td> <span class="Bold">Ingredient</span>
</td>
<td align="center"> <span class="Bold">Molecular Formula</span>
</td>
<td align="center"> <span class="Bold">Molecular Weight</span>
</td>
</tr>
<tr class="Last">
<td> Mannitol USP</td>
<td align="center"> <img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d12cc802-b538-4065-a264-f474ff3b3043&amp;name=mannitol-injection-usp-in-excel-1.jpg">
</td>
<td align="center"> 182.17</td>
</tr>
</tbody>
</table>
<p>The EXCEL® Container is Latex-free, PVC-free, and DEHP-free.</p>
<p>The plastic container is made from a multilayered film specifically developed for parenteral drugs. It contains no plasticizers. The solution contact layer is a rubberized copolymer of ethylene and propylene. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. The container-solution unit is a closed system and is not dependent upon entry of external air during administration. The container is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary. Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period. </p>
<p>The closure system has two ports; the one for the administration set has a tamper evident plastic protector and the other is a medication addition site. Refer to the Directions for Use of the container.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_971f4bbd-5357-4ce6-9bf0-c32dcef796ca"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Mannitol Injection USP is one of the nonelectrolyte, obligatory, osmotic diuretics. It is freely filterable at the renal glomerulus, only poorly reabsorbed by the renal tubule, not secreted by the tubule, and is pharmacologically inert.</p>
<p>Mannitol, when administered intravenously, exerts its osmotic effect as a solute of relatively small molecular size being largely confined to the extracellular space. Only relatively small amounts of the dose administered is metabolized. Mannitol is readily diffused through the glomerulus of the kidney over a wide range of normal and impaired kidney function. In this fashion, approximately 80% of a 100 gram dose of mannitol will appear in the urine in three hours with lesser amounts thereafter. Even at peak concentrations, mannitol will exhibit less than 10% of tubular reabsorption and is not secreted by tubular cells. Mannitol will hinder tubular reabsorption of water and enhance excretion of sodium and chloride by elevating the osmolarity of the glomerular filtrate.</p>
<p>This increase in extracellular osmolarity effected by the intravenous administration of mannitol will induce the movement of intracellular water to the extracellular and vascular spaces. This action underlies the role of mannitol in reducing intracranial pressure, intracranial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and elevated intraocular pressure.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_8b95f733-d51c-4c96-b4da-b24fe670779e"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">20% Mannitol Injection USP is indicated for:</p>
<p>Promotion of <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, in the prevention and/or treatment of the oliguric phase of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> before <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">irreversible renal failure</span> becomes established.<br>Reduction of intracranial pressure and treatment of <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span> by reducing brain <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>.<br>Reduction of elevated intraocular pressure when the pressure cannot be lowered by other means.<br>Promotion of urinary excretion of toxins.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_ac8907e0-ebba-4eba-a972-d29fae35506c"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">20% Mannitol Injection USP is contraindicated in patients with:</p>
<p>Well-established <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span> due to severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>.<br>Severe <span class="product-label-link" type="condition" conceptid="4194173" conceptname="Pulmonary congestion">pulmonary congestion</span> or frank <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>.<br>Active intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> except during craniotomy.<br>Severe <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>.<br>Progressive renal damage or dysfunction after institution of mannitol therapy, including increasing <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>.<br>Progressive <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or <span class="product-label-link" type="condition" conceptid="4194173" conceptname="Pulmonary congestion">pulmonary congestion</span> after institution of mannitol therapy.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_30816032-a698-4bdd-a4c7-ec431cf7f9ff"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">In patients with severe impairment of renal function, a test dose should be utilized (see <span class="Bold"><a href="#LINK_addda274-0840-420c-befb-b270810cfc6b">DOSAGE AND ADMINISTRATION</a></span>). A second test dose may be tried if there is an inadequate response, but no more than two test doses should be attempted.</p>
<p>The obligatory diuretic response following rapid infusion of 20% Mannitol Injection USP may further aggravate preexisting hemoconcentration. Excessive loss of water and electrolytes may lead to serious imbalances. Serum sodium and potassium should be carefully monitored during mannitol administration.</p>
<p>If urine output continues to decline during mannitol infusion, the patient's clinical status should be closely reviewed and mannitol infusion suspended if necessary. Accumulation of mannitol may result in overexpansion of the extracellular fluid which may intensify existing or latent <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</p>
<p>Excessive loss of water and electrolytes may lead to serious imbalances. With rapid or prolonged administration of mannitol, loss of water in excess of electrolytes can cause <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">hypernatremia</span>. Electrolyte measurements including sodium and potassium are therefore of vital importance in monitoring the infusion of mannitol. </p>
<p>Osmotic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>, a reversible vacuolization of the tubules of no known clinical significance, may proceed to severe irreversible <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrosis</span>, requiring close monitoring during mannitol infusion.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_e914361b-da5d-4de9-b793-7dc1cbc016d3"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_808ffd44-9b5e-4065-81c7-345b127e316a"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during parenteral therapy with a mannitol solution.</p>
<p>This solution should be used with care in patients with <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="194406" conceptname="Urinary tract obstruction">urinary tract obstruction</span>, or impending or frank cardiac decompensation.</p>
<p>The cardiovascular status of the patient should be carefully evaluated before rapidly administering mannitol since sudden expansion of the extracellular fluid may lead to fulminating <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</p>
<p>Shifting of sodium-free intracellular fluid into the extracellular compartment following mannitol infusion may lower serum sodium concentration and aggravate preexisting <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
<p>Mannitol administration may obscure and intensify inadequate hydration or <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span> by sustaining <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>.</p>
<p>Electrolyte-free mannitol injection should not be given conjointly with blood. If it is essential that blood be given simultaneously, at least 20 mEq of sodium chloride should be added to each liter of mannitol solution to avoid pseudoagglutination. In no other instance should additions be made to 20% Mannitol Injection USP. The addition of sodium chloride to 20% mannitol solution may result in precipitation of mannitol. The final infusate should therefore be inspected for cloudiness or precipitation immediately after mixing, prior to administration, and periodically during administration.</p>
<p>Solutions of mannitol may crystallize when exposed to low temperatures. Concentrations greater than 15% have a greater tendency to crystallization. Inspect for crystals prior to administration. If crystals are observed, the container should be warmed by appropriate means to not greater than 60°C, shaken, then cooled to body temperature before administering. If all crystals cannot be completely redissolved, the container must be rejected. Administer intravenously using sterile, <span class="Bold">filter-type</span> administration set.</p>
<p>Do not use plastic container in series connection.</p>
<p>If administration is controlled by a pumping device, care must be taken to discontinue pumping action before the container runs dry or <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span> may result. If administration is not controlled by a pumping device, refrain from applying excessive pressure (&gt;300mmHg) causing distortion to the container such as wringing or twisting. Such handling could result in  breakage of the container.</p>
<p>This solution is intended for intravenous administration using sterile equipment. It is recommended that intravenous administration apparatus be replaced at least once every 24 hours.</p>
<p>Use only if solution is clear and container and seals are intact.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="LINK_195fce1d-2665-43c9-8871-28bb10d46dd2"></a><a name="section-7.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Although blood levels of mannitol can be measured, there is little if any clinical virtue in doing so. The appropriate monitoring of blood levels of sodium and potassium; degree of hemoconcentration or hemodilution, if any; indices of renal, cardiac and pulmonary function are paramount in avoiding excessive fluid and electrolyte shifts. The routine features of physical examination and clinical chemistries suffice in achieving an adequate degree of appropriate patient monitoring.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_5a81fb56-5c8a-464d-983a-786eb77fe117"></a><a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, mutagenesis, impairment of fertility</h2>
<p class="First">Long term studies in animals to evaluate the carcinogenic and mutagenic potential or the effect on fertility of 20% Mannitol Injection USP have not been conducted.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_5066625e-be3d-426a-af6f-c05fb6f57d27"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_67cd6ec8-b042-4886-bd01-ad01444aa339"></a><a name="section-7.4.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<p class="First">Pregnancy Category C. Animal reproduction studies have not been conducted with 20% Mannitol Injection USP. It is also not known whether 20% Mannitol Injection USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. 20% Mannitol Injection USP should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_78023479-7051-44bc-b2ac-667ac68ebcb3"></a><a name="section-7.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when 20% Mannitol Injection USP is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_74511a37-2455-4978-a30b-1076956680a5"></a><a name="section-7.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in children below the age of 12 years have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_dcf2e230-5046-4e16-a30b-662a52bf8791"></a><a name="section-7.7"></a><p></p>
<h2>Usage in Children</h2>
<p class="First">Dosage requirements for patients 12 years of age and under have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_850debe9-3928-4241-81d0-db6c74e7870b"></a><a name="section-7.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of 20% Mannitol Injection USP did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_8ca744de-980a-4c10-a252-76bef6263d2b"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Reactions which may occur because of the solution or the technique of administration include febrile response, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> at the site of injection, <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> or <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> extending from the site of injection, <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> and <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span>.</p>
<p>Extensive use of mannitol over the last several decades has produced recorded adverse events, in a variety of clinical settings, that are isolated or idiosyncratic in nature. None of these adverse reactions have occurred with any great frequency nor with any security in attributing them to mannitol.</p>
<p>The inability to clearly exclude the drug related nature of such events in these isolated reports prompts the necessity to list the reactions that have been observed in patients during or following mannitol infusion. In this fashion, patients have exhibited <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, local <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4317266" conceptname="Skin necrosis">skin necrosis</span> and <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> at the site of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and angina-like <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pains</span>.</p>
<p>Of far greater clinical significance is a variety of events that are related to inappropriate recognition and monitoring of fluid shifts. These are not intrinsic adverse reactions to the drug but the consequence of manipulating osmolarity by any agency in a therapeutically inappropriate manner. Failure to recognize severe impairment of renal function with the high likelihood of nondiuretic response can lead to aggravated <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> of tissues and increased vascular fluid load. Induced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> in the presence of preexisting hemoconcentration and preexisting deficiency of water and electrolytes can lead to serious imbalances. Expansion of the extracellular space can aggravate cardiac decompensation or induce it in the presence of latent <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. <span class="product-label-link" type="condition" conceptid="4194173" conceptname="Pulmonary congestion">Pulmonary congestion</span> or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> can be seriously aggravated with the expansion of the extracellular and therefore intravascular fluid load. Hemodilution and dilution of the extracellular fluid space by osmotic shift of water can induce or aggravate preexisting <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
<p>If unrecognized, such fluid and/or electrolyte shift can produce the reported adverse reactions of <span class="product-label-link" type="condition" conceptid="4194173" conceptname="Pulmonary congestion">pulmonary congestion</span>, <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, electrolyte loss, dryness of mouth, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive cardiac failure</span>.</p>
<p>These are not truly adverse reactions to the drug and can be appropriately prevented by evaluation of degree of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> with a test dose response to mannitol when indicated; evaluation of <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span> and <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>; sodium and potassium levels; hemodilution or hemoconcentration; and evaluation of renal, cardiac and pulmonary function at the onset of therapy.</p>
<p>Too rapid infusion of hypertonic solutions may cause local <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and venous irritation. Rate of administration should be adjusted according to tolerance. Use of the largest peripheral vein and a small bore needle is recommended. (See <span class="Bold"><a href="#LINK_addda274-0840-420c-befb-b270810cfc6b">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<p>The physician should also be alert to the possibility of adverse reactions to drug additives. Prescribing information for drug additives to be administered in this manner should be consulted.</p>
<p>If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_441784ee-0d7b-4f3f-8df8-119399c0a43d"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In the event of a fluid or solute overload during parenteral therapy, reevaluate the patient's condition, and institute appropriate corrective treatment. </p>
<p>Larger doses than recommended may result in increased electrolyte excretion, particularly sodium, chloride, and potassium. <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Sodium depletion</span> can result in orthostatic <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and/or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and decreased central venous pressure. Chloride metabolism closely follows that of sodium. Potassium deficit can impair neuromuscular function and cause <span class="product-label-link" type="condition" conceptid="4311399" conceptname="Dilatation of intestine">intestinal dilatation</span> and <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>. </p>
<p>Mannitol may cause <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> or <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span> if urine flow is inadequate. See <span class="Bold"><a href="#LINK_30816032-a698-4bdd-a4c7-ec431cf7f9ff">WARNINGS</a></span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_addda274-0840-420c-befb-b270810cfc6b"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">This solution is for intravenous use only.</p>
<p>The total dosage, concentration, and rate of administration should be governed by the nature and severity of the condition being treated, and the patient's fluid requirement and urinary output. The adult dosage ranges from 50 to 200 g in a 24-hour period, but in most cases an adequate response will be achieved at a usual dosage of approximately 100 g/24 hours. The rate of administration is usually adjusted to maintain a urine flow of at least 30 to 50 mL/hour. Lower mannitol concentrations and solutions containing sodium chloride are useful in preventing <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> and <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span>. This outline of administration and dosage is only a general guide to therapy.</p>
<p>Dosage requirements for patients 12 years of age and under have not been established. As with adults, dose is dependent on weight, clinical condition, and laboratory results. Follow recommendations of appropriate pediatric reference text.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2ade1e9e-f428-4d9a-9194-20c323b8e02c"></a><a name="section-10.1"></a><p></p>
<h2>Test Dose</h2>
<p class="First">A test dose of mannitol should be given prior to instituting therapy for patients with marked <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> or those believed to have inadequate renal function. Such test doses may be approximately 0.2 g/kg body weight (about 75 mL of a 20% solution) infused in a period of 3 to 5 minutes to produce a urine flow of at least 30 to 50 mL/hour. If urine flow does not increase, a second test dose may be given. If response is inadequate, the patient should be reevaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_195f6f67-b959-4cc2-82b7-2f231b5ef3a9"></a><a name="section-10.2"></a><p></p>
<h2>Prevention of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute Renal Failure</span> (<span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">Oliguria</span>)</h2>
<p class="First">When used during cardiovascular and other types of surgery, 50 to 100 g of mannitol may be given.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ad6b89d4-b5c5-45f0-ba58-66844a9db78b"></a><a name="section-10.3"></a><p></p>
<h2>Treatment of <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">Oliguria</span></h2>
<p class="First">The usual dose for treatment of <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> is 100 g administered as a 20% solution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_86daf0c3-a136-4e70-bfc1-4a248a028308"></a><a name="section-10.4"></a><p></p>
<h2>Reduction of Intraocular Pressure</h2>
<p class="First">A dose of 1.5 to 2.0 g/kg as a 20% solution (7.5 to 10 mL/kg) may be given over a period as short as 30 minutes in order to obtain a prompt and maximal effect. When used preoperatively the dose should be given one to one and one-half hours before surgery to achieve maximal reduction of intraocular pressure before operation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e13e55f7-30de-4eb3-a621-bb065d0e2735"></a><a name="section-10.5"></a><p></p>
<h2>Reduction of Intracranial Pressure</h2>
<p class="First">Usually a maximum reduction in intracranial pressure in adults can be achieved with a dose of 0.25 g/kg given not more frequently than every six to eight hours. An osmotic gradient between the blood and cerebrospinal fluid of approximately 10 mOsmol will yield a satisfactory reduction in intracranial pressure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_884617ba-4adf-455a-aa59-4b5e4d5babba"></a><a name="section-10.6"></a><p></p>
<h2>Adjunctive Therapy for <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Intoxications</span></h2>
<p class="First">As an agent to promote <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> in <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxications</span>, mannitol is indicated. The concentration will depend upon the fluid requirement and urinary output of the patient.</p>
<p>Measurement of glomerular filtration rate by creatinine clearance may be useful for determination of dosage.</p>
<p>It is recommended that 20% Mannitol Injection USP be administered through a blood filter set to ensure against infusion of mannitol crystals.</p>
<p>When a hypertonic solution is to be administered peripherally, it should be slowly infused through a small bore needle, placed well within the lumen of a large vein to minimize venous irritation. Carefully avoid infiltration.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Use of a final filter is recommended during administration of all parenteral solutions, where possible.</p>
<p>This solution is intended for intravenous administration using sterile equipment.</p>
<p>The use of supplemental additive medication is not recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_a9b1dcfd-678d-478d-a30b-91df2c34df5b"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">20% Mannitol Injection USP is supplied sterile and nonpyrogenic in EXCEL<span class="Sup">®</span> Containers. The 500 mL and 250 mL containers are packaged 24 per case.</p>
<table>
<col>
<col>
<col>
<thead><tr class="First Last">
<th align="center" valign="bottom"> NDC</th>
<th align="center" valign="bottom"> Cat. No.</th>
<th align="center" valign="bottom"> Size</th>
</tr></thead>
<tbody>
<tr class="First">
<td valign="bottom"> 20% Mannitol Injection USP</td>
<td align="center" valign="bottom"> </td>
<td align="center" valign="bottom"> </td>
</tr>
<tr>
<td align="center" valign="bottom"> 0264-7578-10</td>
<td align="center" valign="bottom"> L5781</td>
<td align="center" valign="bottom"> 500 mL</td>
</tr>
<tr class="Last">
<td align="center" valign="bottom"> 0264-7578-20</td>
<td align="center" valign="bottom"> L5782</td>
<td align="center" valign="bottom"> 250 mL</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="LINK_a3fac8dd-19ce-4cd9-adef-4cf28ffbd395"></a><a name="section-11.1"></a><p></p>
<h2></h2>
<p class="First">Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended that the product be stored at room temperature (25°C).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_917ceea9-0e41-45dd-a57f-f2065f4016fd"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
<p>Revised: December 2009<br>EXCEL is a registered trademark of B. Braun Medical Inc.</p>
</div>
<div class="Section" data-sectionCode="59845-8">
<a name="LINK_5c4c8f56-b626-4a59-94c2-658afa5d7f4d"></a><a name="section-13"></a><p></p>
<h1>Directions for Use of EXCEL® Container</h1>
<p class="First"><span class="Bold">Do not admix with other drugs.</span></p>
<p><span class="Bold">Caution:</span> Do not use plastic container in series connection.</p>
<p><span class="Bold">To Open</span></p>
<p>Tear overwrap and remove solution container. Check for minute leaks by squeezing solution container firmly. If leaks are found, discard solution as <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> may be impaired.</p>
<p><span class="Bold">NOTE:</span> Before use, perform the following checks:</p>
<ul class="Disk">
<li> Inspect each container. Read the label. Ensure solution is the one ordered and is within the expiration date. 
</li>
<li> Invert container and carefully inspect the solution in good light for cloudiness, haze, or particulate matter. Any container which is suspect should not be used. 
</li>
<li> Use only if solution is clear and container and seals are intact.</li>
</ul>
<p>Preparation for Administration</p>
<ol class="Arabic">
<li>Remove plastic protector from sterile set port at bottom of container. 
</li>
<li>Attach administration set. Refer to complete directions accompanying set.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_15f818c8-990b-4543-bc05-e5b134ca6674"></a><a name="section-14"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">B. Braun Medical Inc.</span><br>Irvine, CA  92614-5895 USA <br>Made in USA</p>
<p>Y36-002-734</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_8a23a9e4-de5d-4b5d-a4d1-a242c61729ef"></a><a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 500 mL Container Label</h1>
<p class="First"><span class="Bold">20% Mannitol <br>Injection USP</span></p>
<p><span class="Bold">REF L5781<br>NDC 0264-7578-10<br>HK 22605</span></p>
<p><span class="Bold">500 mL</span><br><span class="Italics">EXCEL</span><span class="Sup">®</span><span class="Italics"> CONTAINER</span></p>
<p><span class="Bold">Each 100 mL contains: Mannitol USP 20 g <br>Water for Injection USP qs</span></p>
<p><span class="Bold">pH: 5.3 (4.5-7.0) <br>Calc. Osmolarity: 1100 mOsmol/liter, hypertonic </span></p>
<p>Sterile, nonpyrogenic. Single dose container.</p>
<p>Do not use in series connection. <br>For intravenous use only. Use only if solution is clear <br>and container and seals are intact.</p>
<p><span class="Bold">WARNING: Do not admix with other drugs.</span></p>
<p>Dissolve any mannitol crystals by heating (≤60°C) and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>; <br>cool before administration. Reject container if crystals are not <br>completely redissolved.</p>
<p>Recommended Storage: Room temperature (25°C). <br>Avoid excessive heat. Protect from freezing. See Package Insert. <br><img alt="Latex free, DEHP free and PVC free" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d12cc802-b538-4065-a264-f474ff3b3043&amp;name=mannitol-injection-usp-in-excel-2.jpg"><br>Rx only<br><img alt="Other symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d12cc802-b538-4065-a264-f474ff3b3043&amp;name=mannitol-injection-usp-in-excel-3.jpg"><br>EXCEL is a registered trademark of B. Braun Medical Inc.</p>
<p><span class="Bold">B. Braun Medical Inc.</span><br>Irvine, CA 92614-5895 USA<br>1-800-227-2862<br>www.bbraun.com<br>Made in USA</p>
<p>Y94-003-060<br>LD-110-2</p>
<p>Do not remove overwrap until ready for use. After removing the <br>overwrap, check for minute leaks by squeezing container firmly. If <br>leaks are found, discard solution as <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> may be impaired.</p>
<p>EXP<br>LOT</p>
<div class="Figure"><img alt="Container Label L5781" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d12cc802-b538-4065-a264-f474ff3b3043&amp;name=mannitol-injection-usp-in-excel-4.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_853281ee-1c76-4d32-bdc5-b45091d0eb1b"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 250 mL Container Label</h1>
<p class="First"><span class="Bold">20% Mannitol <br>Injection USP</span></p>
<p><span class="Bold">REF L5782<br>NDC 0264-7578-20 <br>HK 22605 </span></p>
<p><span class="Bold">250 mL <br></span><span class="Italics">EXCEL</span><span class="Sup">®</span><span class="Italics"> Container</span></p>
<p><span class="Bold">Each 100 mL contains: <br>Mannitol USP 20 g <br>Water for Injection USP qs</span></p>
<p><span class="Bold">pH: 5.3 (4.5-7.0) <br>Calc. Osmolarity: 1100 mOsmol/liter, hypertonic </span></p>
<p>Sterile, nonpyrogenic. Single dose container</p>
<p>Do not use in series connection. <br>For intravenous use only. Use only if solution <br>is clear and container and seals are intact.</p>
<p><span class="Bold">WARNING: Do not admix with other drugs.</span></p>
<p>Dissolve any mannitol crystals by heating (≤60°C) <br>and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>; cool before administration. Reject <br>container if crystals are not completely redissolved.</p>
<p>Recommended Storage: <br>Room temperature (25°C). Avoid excessive heat. <br>Protect from freezing. See Package Insert.<br><img alt="Latex free, DEHP free and PVC free" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d12cc802-b538-4065-a264-f474ff3b3043&amp;name=mannitol-injection-usp-in-excel-5.jpg"><br>Rx only<br><img alt="Other symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d12cc802-b538-4065-a264-f474ff3b3043&amp;name=mannitol-injection-usp-in-excel-6.jpg"><br>EXCEL is a registered trademark of B. Braun Medical Inc.</p>
<p><span class="Bold">B. Braun Medical Inc.</span><br>Irvine CA 92614-5895 USA<br>1-800-227-2862<br><a href="#www.bbraun.com">www.bbraun.com</a><br>Made in USA</p>
<p>Y94-003-061<br>LD-109-2</p>
<p>Do not remove overwrap until ready for use. After <br>removing the overwrap, check for minute leaks by <br>squeezing container firmly. If leaks are found, discard <br>solution as <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> may be impaired.</p>
<p>EXP<br>LOT</p>
<div class="Figure"><img alt="Container Label L5782" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d12cc802-b538-4065-a264-f474ff3b3043&amp;name=mannitol-injection-usp-in-excel-7.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MANNITOL 		
					</strong><br><span class="contentTableReg">mannitol injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0264-7578</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MANNITOL</strong> (MANNITOL) </td>
<td class="formItem">MANNITOL</td>
<td class="formItem">20 g  in 100 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0264-7578-10</td>
<td class="formItem">24  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">500 mL in 1 CONTAINER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0264-7578-20</td>
<td class="formItem">24  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">250 mL in 1 CONTAINER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020006</td>
<td class="formItem">07/26/1993</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>B. Braun Medical Inc.
							(002397347)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bdb4a9b7-1768-44c8-ab30-b16ba2d28cfd</div>
<div>Set id: d12cc802-b538-4065-a264-f474ff3b3043</div>
<div>Version: 6</div>
<div>Effective Time: 20140325</div>
</div>
</div> <div class="DistributorName">B. Braun Medical Inc.</div></p>
</body></html>
